PL2552461T3 - Tetratiomolibdenian do stosowania w leczeniu uszkodzenia niedokrwiennoreperfuzyjnego głowy lub mózgu - Google Patents

Tetratiomolibdenian do stosowania w leczeniu uszkodzenia niedokrwiennoreperfuzyjnego głowy lub mózgu

Info

Publication number
PL2552461T3
PL2552461T3 PL11716626T PL11716626T PL2552461T3 PL 2552461 T3 PL2552461 T3 PL 2552461T3 PL 11716626 T PL11716626 T PL 11716626T PL 11716626 T PL11716626 T PL 11716626T PL 2552461 T3 PL2552461 T3 PL 2552461T3
Authority
PL
Poland
Prior art keywords
tetrathiomolybdate
ischemia
brain
head
treatment
Prior art date
Application number
PL11716626T
Other languages
English (en)
Inventor
Mervyn Singer
John Francis Martin
Alex Peter Dyson
Original Assignee
Magnus Ttm Ic
Mervyn Singer
John Francis Martin
Alex Peter Dyson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magnus Ttm Ic, Mervyn Singer, John Francis Martin, Alex Peter Dyson filed Critical Magnus Ttm Ic
Publication of PL2552461T3 publication Critical patent/PL2552461T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11716626T 2010-03-30 2011-03-30 Tetratiomolibdenian do stosowania w leczeniu uszkodzenia niedokrwiennoreperfuzyjnego głowy lub mózgu PL2552461T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1005394.0A GB201005394D0 (en) 2010-03-30 2010-03-30 Therapy
EP11716626.4A EP2552461B1 (en) 2010-03-30 2011-03-30 Tetrathiomolybdate for use in the treatment of ischemia-reperfusion injury of the head or brain
PCT/GB2011/050653 WO2011121354A1 (en) 2010-03-30 2011-03-30 The therapeutic use of tetrathiomolybdate

Publications (1)

Publication Number Publication Date
PL2552461T3 true PL2552461T3 (pl) 2015-04-30

Family

ID=42228650

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11716626T PL2552461T3 (pl) 2010-03-30 2011-03-30 Tetratiomolibdenian do stosowania w leczeniu uszkodzenia niedokrwiennoreperfuzyjnego głowy lub mózgu
PL12189630T PL2556834T3 (pl) 2010-03-30 2011-03-30 Tetratiomolibdenian do stosowania w leczeniu uszkodzenia niedokrwiennoreperfuzyjnego serca

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12189630T PL2556834T3 (pl) 2010-03-30 2011-03-30 Tetratiomolibdenian do stosowania w leczeniu uszkodzenia niedokrwiennoreperfuzyjnego serca

Country Status (12)

Country Link
EP (3) EP2552461B1 (pl)
JP (2) JP5674917B2 (pl)
CN (1) CN103096903A (pl)
BR (1) BR112012024704A8 (pl)
DK (3) DK2842562T3 (pl)
ES (3) ES2529115T3 (pl)
GB (1) GB201005394D0 (pl)
HU (1) HUE024155T2 (pl)
PL (2) PL2552461T3 (pl)
PT (2) PT2552461E (pl)
SI (2) SI2552461T1 (pl)
WO (1) WO2011121354A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478455B2 (en) 2010-03-30 2019-11-19 Ucl Business Ltd Therapeutic use of tetrathiomolybdate
EP2578221A1 (en) * 2011-10-04 2013-04-10 Magnus Intellectual Property Ltd. The therapeutic use of tetrathiomolybdate
WO2017019892A1 (en) * 2015-07-28 2017-02-02 Insmed Incorporated Compositions comprising copper chelators and methods of use thereof for treating vasculopathies
DK3529231T3 (da) 2016-10-21 2021-05-31 Ucl Business Ltd Krystallinsk diethylamintetrathiomolybdat og farmaceutiske anvendelser deraf

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
ES2188261T3 (es) * 1998-09-04 2003-06-16 Univ Michigan Tiomolibdato asociado a, al menos, un hidrato de carbono y su uso en la prevencion o tratamiento de enfermedades caracterizadas por una vacularizacion aberrante, tales como cancer, degeneracion macular tipo humedo, artritis reumatoides.
AU2003222513A1 (en) * 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
CA2490541A1 (en) * 2002-05-24 2003-12-04 The Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
WO2004017957A1 (en) * 2002-08-20 2004-03-04 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
WO2007084818A2 (en) * 2006-01-10 2007-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
WO2008100653A2 (en) * 2007-01-08 2008-08-21 The Regents Of The University Of Michigan Copper lowering treatment of cardiac disease

Also Published As

Publication number Publication date
JP2013523709A (ja) 2013-06-17
EP2552461B1 (en) 2014-12-17
BR112012024704A8 (pt) 2021-03-23
SI2556834T1 (sl) 2015-05-29
EP2842562A1 (en) 2015-03-04
ES2529115T3 (es) 2015-02-17
EP2556834A1 (en) 2013-02-13
PL2556834T3 (pl) 2015-04-30
ES2573809T3 (es) 2016-06-10
PT2556834E (pt) 2015-02-10
ES2529225T3 (es) 2015-02-18
JP2015057450A (ja) 2015-03-26
PT2552461E (pt) 2015-02-10
JP6038867B2 (ja) 2016-12-07
JP5674917B2 (ja) 2015-02-25
HUE024155T2 (en) 2016-02-29
DK2552461T3 (en) 2015-02-09
CN103096903A (zh) 2013-05-08
GB201005394D0 (en) 2010-05-12
EP2556834B1 (en) 2014-11-26
BR112012024704A2 (pt) 2021-03-02
DK2556834T3 (en) 2015-02-09
EP2842562B1 (en) 2016-04-27
DK2842562T3 (en) 2016-06-06
EP2552461A1 (en) 2013-02-06
WO2011121354A1 (en) 2011-10-06
SI2552461T1 (sl) 2015-03-31

Similar Documents

Publication Publication Date Title
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
PT3400943T (pt) Compostos para serem utilizados no tratamendo de metástase no cérebro num doente com cancro da mama positivo para erbb2.
ZA201208413B (en) Skin treatment composition
ZA201502290B (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and ist associated disorders
IL237125A0 (en) Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors
HUS2000020I1 (hu) Ciklezonid a légúti betegségek kezelésére lovaknál
IL239374B (en) Preparations and methods for treating brain tumors
HUE040348T2 (hu) Bõrfiatalító kozmetikai készítmény
PL2830645T3 (pl) Neuregulina do zastosowania w leczeniu uszkodzenia nerwu obwodowego
IL235272B (en) Alfentanil preparation for the treatment of acute pain
SI2552461T1 (sl) Tetratiomolibdat za uporabo pri zdravljenju ishemične-reperfuzijske poškodbe glave ali možganov
ZA201208568B (en) Skin treatment composition
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
PL2872176T3 (pl) Karboranyloporfiryny do stosowania w leczeniu raka
EP2616485A4 (en) STEPPED DEVELOPED PEPTIDE FOR THE TREATMENT OF BRAIN INJURIES
PL2531124T3 (pl) Urządzenia do leczenia zmian skórnych
ZA201300413B (en) Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders
PL2819655T3 (pl) Modafinil do stosowania w leczeniu uzależnionych od kokainy
EP2531186A4 (en) TREATMENT OF HAIR DRESSES
GB2477546B (en) Skin treatment apparatus
GB201001659D0 (en) Body treatment product
GB201016834D0 (en) Composition for skin treatment
GB201016836D0 (en) Composition for skin treatment